Merck’s Allergopharma opens €42m biopharmaceutical plant

pharmafile | March 7, 2017 | News story | Manufacturing and Production Allergopharma, Merck 

Allergopharma, a subsidiary of Germany’s Merck, has completed construction on its new €42 million biopharmaceutical facility and declared it open for business.

Work on the 6,000 square metre plant in Reinbek, near Hamburg, began in 2013, with Allergopharma stating that the new operation would aid its expansion into such as China. The company focuses on the development and production of immunotherapies for the treatment of allergies such as allergic rhinitis and allergic asthma.

Chief Operating Officer Simon Sturge stressed the significance of the new facility in a statement: ‘‘with this €42 million investment Merck is supporting the Reinbek site in order to expand the allergies business on a global scale. The new production building is part of this global expansion, and will support our growing business in the allergy marketplace.”

CEO of Allergopharma Marco Linari added: “From a technology point of view, the new biopharmaceutical production is a quantum leap. It means an increase in supply safety for patients, a further improvement of product quality and future innovations towards improving therapy.”

Matt Fellows

Related Content

Merck invests €35m in biosafety testing in Scotland

Merck has announced that it has invested €35m in biosafety testing at its sites in …

NICE rejects Merck Serono’s Bavencio for urothelial cancer

The use of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based …

Merck kidney and uterus cancer treatments granted priority review by FDA

The FDA has granted priority review for Merck (MSD) and Eisai’s application for two new …

Latest content